Biotechnology Industry News

Need More Information On This Industry?

See It All Now! Free Trial

866-704-3389

Biotechnology Industry News

YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA (4:00:00pm Mon Nov. 23, 2009 CDT)

MISSISSAUGA, ON, Nov. 23 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that Cytopia (ASX:CYT) has commenced enrollment of a Phase I/II trial evaluating CYT387, a potent, orally-administered JAK1/JAK2 inhibitor. The trial is being conducted at Mayo Clinic in Rochester, Minnesota. A proposal to merge Cytopia into YM has been previously announced and is pending approval by Cytopia shareholders, Australian court and other regulatory approvals. ...

PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend (3:56:00pm Mon Nov. 23, 2009 CDT)

INCLINE VILLAGE, Nev., Nov. 23 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that NASDAQ has established November 27, 2009 as the ex-dividend date for its $200 million special dividend to stockholders resulting from the securitization transaction completed on November 2, 2009. The dividend will be paid on December 15, 2009 to all stockholders of record on the record date, December 1, 2009. NASDAQ has set the approximate per share amount of the dividend at $1.67 per share of common stock for purposes of the ex-dividend date on November 27, 2009. This approximate per share amount is based on the number of shares of the Company's common stock outstanding on September 30, 2009. ...

Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter (3:05:00pm Mon Nov. 23, 2009 CDT)

POINT RICHMOND, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on January 20, 2010 to discuss the Complete Response Letter regarding the New Drug Application (NDA) for Intermezzo® (zolpidem tartrate sublingual tablet). As previously announced, the Complete Response Letter, received by Transcept on October 28, 2009, indicated that the FDA could not approve the NDA in its present form. The NDA seeks approval to market Intermezzo® for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep. ...

Beckman Coulter to Present at the 2009 Piper Jaffray Healthcare Conference (2:19:00pm Mon Nov. 23, 2009 CDT)

ORANGE COUNTY, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE: BEC), a leading developer, manufacturer, and marketer of products that simplify, automate, and innovate complex biomedical testing, announced today that Allan Harris, Beckman Coulter's vice president of strategy, will present at the Piper Jaffray Healthcare Conference on Wednesday, December 2, 2009 at 12:00 p.m. (ET). ...

Oncolytics Biotech(R) Inc. Closes US$12.75 Million Unit Offering (8:19:00am Mon Nov. 23, 2009 CDT)

CALGARY, AB, Nov. 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ:ONCY) announced today that it has closed its previously announced US$12,750,000 offering in which a syndicate of underwriters purchased 4,250,000 units of the Company, each unit comprised of one common share and 0.4 of a common share purchase warrant, at a price of US$3.00 per unit. Each whole common share purchase warrant entitles the holder to acquire one common share of Oncolytics upon payment of US$3.50 for a five year period commencing on the closing date of the offering, subject to an acceleration of the expiry date in certain circumstances. Oppenheimer & Co. Inc. acted as the sole book-running manager for the offering. Canaccord Capital Corporation and Bloom Burton & Co. acted as Canadian co-managers for the offering. ...

Richard T. Crowder Joins Neogen's Board of Directors (8:15:00am Mon Nov. 23, 2009 CDT)

LANSING, Mich., Nov. 23 /PRNewswire-FirstCall/ -- Neogen Corporation (Nasdaq: NEOG) announced today that Richard T. Crowder, Ph.D., was elected to Neogen's Board of Directors at the company's recent annual meeting of shareholders. ...

Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009 (7:30:00am Mon Nov. 23, 2009 CDT)

THE WOODLANDS, Texas, Nov. 23 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that top-line data from its Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS) will be presented at GASTRO 2009 in London this week. Results from the study, which showed a significant improvement in IBS symptoms, will be presented by Dr. Philip M. Brown, Lexicon's senior vice president of clinical development, on November 25, 2009 at 2:30 pm local time at the session entitled, "Therapeutic insights in functional digestive disorders." ...

Pearl Therapeutics Appoints Howie Rosen to Board of Directors (7:00:00am Mon Nov. 23, 2009 CDT)

REDWOOD CITY, Calif., Nov. 23 /PRNewswire/ -- Pearl Therapeutics Inc., a biopharmaceutical company developing therapeutic products for the treatment of chronic respiratory diseases, today announced the appointment of Howie Rosen to the company's Board of Directors. Mr. Rosen has 25 years of experience in the pharmaceutical and biotechnology industries, including key roles at Gilead Sciences and ALZA Corporation. His appointment increases the number of directors on Pearl's Board to six. ...

Cornerstone Therapeutics to Present at the 21st Annual Piper Jaffray Health Care Conference (7:00:00am Mon Nov. 23, 2009 CDT)

CARY, N.C., Nov. 23 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that Craig A. Collard, President and Chief Executive Officer, will be presenting a corporate overview at the 21st Annual Piper Jaffray Health Care Conference at 3:30 PM ET on Wednesday, December 2, 2009 at The New York Palace Hotel in New York City. ...

Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis (7:00:00am Mon Nov. 23, 2009 CDT)

MALVERN, Pa. and FRAZER, Pa., Nov. 23 /PRNewswire-FirstCall/ -- Ception Therapeutics, Inc., a privately held biopharmaceutical company, and Cephalon, Inc. (Nasdaq: CEPH) today announced results from a Phase IIb/III clinical trial for CINQUIL(TM) (reslizumab) as a treatment for pediatric eosinophilic esophagitis (EoE). The study was designed to evaluate improvement in the co-primary endpoints of changes in esophageal eosinophil levels and clinical symptoms. Analyses of the data indicated that patients treated with CINQUIL showed a statistically significant reduction in esophageal eosinophil levels versus placebo. In the second co-primary endpoint, patients treated with CINQUIL showed an improvement in their clinical symptoms; however, placebo treated patients also experienced an unexpectedly large improvement in their symptoms. Therefore, the study did not achieve statistical significance for this endpoint. CINQUIL was well tolerated in the study, with an adverse event profile comparable to placebo. Ception and Cephalon continue to fully analyze the data and are planning to perform an analysis of an ongoing open-label extension study to help further assess the clinical results. ...

Neurobiological Technologies Announces Extraordinary Dividend of $0.18 per Share (7:00:00am Mon Nov. 23, 2009 CDT)

EMERYVILLE, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII) ("NTI") announced today that its board of directors has declared an extraordinary dividend of $0.18 per share of common stock, which will be paid on December 9, 2009 to stockholders of record as of November 30, 2009. The December 9, 2009 extraordinary dividend follows stockholder approval of the dissolution of NTI pursuant to a plan of complete liquidation and dissolution and an earlier extraordinary dividend of $0.75 per share that was paid to shareholders on November 18, 2009. The dividend of $0.18 per share was declared by the board of directors following the Company's recent sale of auction rate securities as disclosed in the Quarterly Report on Form 10-Q filed with the SEC on November 16, 2009. ...

Excellence in Healthcare Innovation Recognized by Frost & Sullivan (6:45:00am Mon Nov. 23, 2009 CDT)

MOUNTAIN VIEW, Calif., Nov. 23 /PRNewswire/ -- Frost & Sullivan, the Growth Partnership Company, honored healthcare companies for demonstrating leadership and innovation Thursday, November 19, 2009 at the Excellence in Healthcare Innovation Awards Banquet held in San Antonio, Texas. ...

Inimex Announces Appointment of New CEO (6:00:00am Mon Nov. 23, 2009 CDT)

BURNABY, BC, Nov. 23 /PRNewswire/ - Inimex Pharmaceuticals, Inc. announced today that it has appointed Michael J. Abrams, Ph.D as its President and CEO. ...

Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director (5:10:00am Mon Nov. 23, 2009 CDT)

SEATTLE, Nov. 23 /PRNewswire/ -- Immune Design Corp. (IDC) announced today that Dr. Bruce L.A. Carter has joined IDC as Executive Chairman. Dr. Carter has a successful track record in biotechnology executive management. He was the former Chief Executive Officer at ZymoGenetics, in Seattle, WA and Chief Scientific Officer at Novo Nordisk, Copenhagen, Denmark. ...

ASTMH Symposium Showcases Efforts To Meet the Need for New Medicines to Treat Infectious Diseases in Developing Countries (12:30:00pm Sat Nov. 21, 2009 CDT)

WASHINGTON, Nov. 21 /PRNewswire/ -- An urgent need for new medicines to treat neglected infectious diseases in the developing world has prompted a growing number of collaborations among academic researchers, non-profit product development partnerships (PDPs), and pharmaceutical and biotechnology companies. As noted today in a symposium at the 58th annual meeting of the American Society of Tropical Medicine and Hygiene (ASTMH), these collaborations are opening up new avenues of access to industry technology, expertise, and capabilities, enabling the harnessing of industry resources for new product innovation. ...

Register for a Free Trial Now!

Call (866) 704-3389 to get started, or fill out this form and we'll contact you to set up your custom trial. Calling from outside the US?

All fields required.